Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02165813
Other study ID # NICEGUT
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date November 2014
Est. completion date June 6, 2021

Study information

Verified date February 2024
Source Telethon Kids Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-centre (RDH and ASH), phase IV, double-blind, randomised, placebo-controlled Bayesian adaptive trial of oral NTZ for the treatment of acute gastroenteritis requiring admission to hospital. A maximum of 300 children aged between three months and less than five years of age will be enrolled. Study participation is from the point of enrolment until 60 days after enrolment. Enrolment will occur within 48 hours of admission to hospital. Enrolled participants will be randomised 1:1 to Nitazoxanide (NTZ) or placebo. Other treatment and management will be as per the standard of care described in the admitting hospital's guidelines and will be ultimately the decision and responsibility of the named medical consultant. Stool samples will be collected at the point of admission. Solicitation of symptoms will be by review of routinely collected medical data recorded in the participant's medical record, and will be supplemented by completion of study specific diary cards after discharge (for the first 210 enrolments). Attempts will be made to contact participants at day 7 after enrolment (by telephone if already discharged) to ascertain symptoms occurring in the intervening period. At days 30 and 60 (for first 210 enrolments ) and Day 60 (for enrolment #211 onwards) after enrolment a clinical record review will be conducted for all participants to ascertain health care attendances following discharge.


Description:

This is a multi-centre (RDH and ASH), phase IV, double-blind, randomised, placebo-controlled Bayesian adaptive trial of oral NTZ for the treatment of acute gastroenteritis requiring admission to hospital. A maximum of 300 children aged between three months and less than five years of age will be enrolled. Study participation is from the point of enrolment until 60 days after enrolment. Enrolment will occur within 48 hours of admission to hospital. Enrolled participants will be randomised 1:1 to Nitazoxanide (NTZ) or placebo. Other treatment and management will be as per the standard of care described in the admitting hospital's guidelines and will be ultimately the decision and responsibility of the named medical consultant. Stool samples will be collected at the point of admission. Solicitation of symptoms will be by review of routinely collected medical data recorded in the participant's medical record, and will be supplemented by completion of study specific diary cards until discharge (for the first 210 enrolments). Attempts will be made to contact participants at day 7 after enrolment (by telephone if already discharged) to ascertain symptoms occurring in the intervening period. At days 30 and 60 (for first 210 enrolments ) and Day 60 (for enrolment #211 onwards) after enrolment a clinical record review will be conducted for all participants to ascertain health care attendances following discharge. The sample size for the study is a maximum of 300 children, randomised on a 1:1 basis to the two study treatment groups. The trial will stop recruiting when pre-specified decision criteria are met based on treatment superiority or trial futility or when 300 children have been enrolled. Based on previously published data it is hypothesised that NTZ treatment will result in a decrease in the median duration of medically significant illness by 1 day. A decrease of one day is considered to be the minimum useful decrease of relevance to the study setting. It is anticipated that there will be minimal lost to follow-up as the primary endpoint will be available for the majority of participants in each arm due to the short interval between enrolment and meeting the criteria for the primary endpoint. The trial will be conducted as a fixed allocation Bayesian adaptive randomised controlled trial. This statistical methods in the protocol are written to be practical and accessible to individuals with an understanding of common clinical trial designs and classical frequentist analytical methods but without training in Bayesian statistics. A formal description of the interim Bayesian data analysis fundamental to this design, which assumes substantial familiarity with Bayesian calculation of posterior distributions conditioned on observed data, is documented in the Statistical Analysis Plan. There is overlap between the protocol and statistical analysis plan so that each may serve an appropriate audience as a standalone description of the statistical methods. Briefly, within the Bayesian framework, the intervention arms are evaluated and sequential Bayesian statistical analyses are used over time to incorporate new trial outcome information to determine if a treatment is superior, inferior, or equivalent, with respect to the primary end-point. Every child will be randomly assigned in a ratio 1:1 to placebo or nitazoxanide. Children will be classified by membership in different strata, where membership will be defined by age and geographical region. Whenever an interim analysis reports superiority, inferiority, or equivalence with respect to the primary end-point this is termed a Statistical Trigger. At any given interim analysis, a Statistical Trigger may be reached for all children or for one or more strata.


Recruitment information / eligibility

Status Terminated
Enrollment 216
Est. completion date June 6, 2021
Est. primary completion date April 21, 2021
Accepts healthy volunteers No
Gender All
Age group 3 Months to 5 Years
Eligibility Inclusion Criteria: 1. Infant /child between =>3 months and <5 years of age 2. Infant/ child identified as Indigenous by the legally responsible care-giver 3. Infant /child has been/will be admitted to hospital for acute infectious gastroenteritis (in the opinion of the admitted doctor and/or study doctor/nurse ) 4. The legally responsible care-giver is willing for their infant/ child to participate in the study and who would be expected to comply with the requirements of the protocol, including being able and willing to be contacted by telephone after discharge where necessary 5. The legally responsible care-giver is willing to allow other parties involved in the treatment of his or her child (including the general practitioner, paediatrician, hospital medical and nursing staff, community clinic staff) to be notified of participation in the trial 6. The legally responsible care-giver is willing to allow to allow the study team to obtain a vaccination history from Australian Childhood Immunisation Register (ACIR) and/or local provider 7. The legally responsible care-giver is willing to allow the study team to obtain an interim medical history from the participant's electronic medical records and/or from the participant's general practitioner for the period from enrolment to study day 60 8. Informed consent for the infant's/child's participation in the study has been given by the legally responsible care-giver Exclusion Criteria: 1. Admitted for =>48 hours at the point of enrolment 2. Duration of symptoms of greater than 14 days without apparent worsening of symptoms consistent with an acute pathology 3. Presence of grossly bloody diarrhoea 4. Clinical suspicion of non-infectious cause (e.g. diagnosed with a pre-existing medical condition predisposing to non-infectious diarrhoea, for example inflammatory bowel disease) except for environmental enteropathy) 5. Contraindication to the study drug or placebo (e.g. allergy) 6. Diagnosis of infection with an enteric pathogen where anti-microbial treatment with an alternative antimicrobial is the standard of care (e.g. Shigella sp.) 7. Inability to tolerate either the oral or nasogastric route (e.g. ileus) 8. Clinical suspicion of intestinal obstruction including bilious vomiting 9. Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection. 10. Receipt of more than 2 weeks of immuno-suppressants or immune modifying drugs, (e.g. prednisolone >0.5 mg/kg/day) 11. Receipt of investigational drug/vaccine, other than the drugs used in the study, within 30 days prior to receiving the first dose of NTZ or their planned use during the study period, until 1 month after the administration of the final dose of NTZ 12. Previously enrolled in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nitazoxanide
Nitazoxanide is a synthetic drug of the nitrothiazolide class. The main metabolite of NTZ is tizoxanide. The active ingredient is Nitazoxanide (2-acetyloxy-N(5-nitro-2-thiazolyl)benzamide), a synthetic agent for oral administration, at a concentration of 100 mg/5 ml.
placebo
An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.

Locations

Country Name City State
Australia Alice Springs Hospital Alice Springs Northern Territory
Australia Royal Darwin Hospital Darwin Northern Territory

Sponsors (3)

Lead Sponsor Collaborator
Telethon Kids Institute Menzies School of Health Research, The University of Western Australia

Country where clinical trial is conducted

Australia, 

References & Publications (1)

Waddington CS, McLeod C, Morris P, Bowen A, Naunton M, Carapetis J, Grimwood K, Robins-Browne R, Kirkwood CD, Baird R, Green D, Andrews R, Fearon D, Francis J, Marsh JA, Snelling T. The NICE-GUT trial protocol: a randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal children. BMJ Open. 2018 Feb 1;8(2):e019632. doi: 10.1136/bmjopen-2017-019632. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Symptom frequency (vomiting, diarrhoea, generally unwell) The proportion of participants experiencing each solicited symptom (vomiting, diarrhoea, generally unwell) on each of study days 0-7 On each of study days 0-7
Other Dehydration frequency and severity The proportion of participants in whom dehydration is present and the severity of dehydration, where present, on each study day using a protocol-specific dehydration score from 0 (not dehydrated) to 3 (severely dehydrated) On each of study days 0-7
Other Time of intravenous, intraosseous or nasogastric rehydration The time interval between either starting intravenous, intraosseous or nasogastric rehydration or enrolment (whichever is the later), and ceasing rehydration or discharge for the first 210 participants. 7 days post randomisation
Other Severity score for each adverse event The maximum daily severity score for each adverse event , where experienced. Will be assessed using a protocol-specific grading system from 0 (normal) to 3 (severe). 0-60 days post randomisation
Primary Time of significant illness The time period of significant illness (defined as the period for which hospitalisation is required for medical reasons) for participants in each study treatment group. Between randomisation and hospital discharge (expected to be within 7 days)
Secondary Time to hospital discharge The time period between enrolment and actual discharge from hospital Between randomisation and hospital discharge (expected to be within 7 days)
See also
  Status Clinical Trial Phase
Completed NCT01168401 - Bivalent Norovirus Vaccine Study Phase 1
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Completed NCT02473887 - Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting Phase 1
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Not yet recruiting NCT01671137 - Probiotic for the Prevention of Functional Disorders in Childhood N/A
Completed NCT01917461 - Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections N/A
Withdrawn NCT00691275 - Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration N/A
Recruiting NCT06025695 - Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks Phase 3
Completed NCT04463082 - Non-invasive Assessment of the Current State of Hydration in Children by Ultrasound N/A
Completed NCT02497417 - A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients N/A
Active, not recruiting NCT03000296 - Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease N/A
Completed NCT01236066 - Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia N/A
Completed NCT01225042 - The Effect of Probiotics on E. Coli Gastroenteritis N/A
Recruiting NCT00987519 - Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age N/A
Terminated NCT01357174 - ROTATEQâ„¢ Post-Marketing Surveillance in the Philippines N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Recruiting NCT01363726 - Surveillance of Rotavirus Gastroenteritis in Children <5 Years N/A
Completed NCT00130832 - Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) Phase 3
Terminated NCT02568189 - Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration N/A
Completed NCT01853124 - Emergency Department Probiotic Treatment of Pediatric Gastroenteritis Phase 3

External Links